Articles tagged with Chemotherapy
Patients with metastatic prostate cancer who received a two-drug combination of chemotherapy and hormone blocker lived longer than those on hormone-blocker alone, surviving for 57.6 months versus 44 months. The treatment also delayed disease progression by six months.
ATF3 is a critical protein that helps repair DNA damage and prevent cancer. When cells experience stress, ATF3 binds to the Tip60 protein, promoting DNA repair and cell response. The study suggests that increasing ATF3 levels could lead to new cancer therapies.
A study published in JAMA Oncology found that chemotherapy was associated with worse quality of life near death for patients who could still perform many life functions. The researchers concluded that chemotherapy use may be unnecessary and potentially harmful for patients with progressive metastatic disease.
Researchers have developed a new drug, CCT245737, that blocks cancer's escape route from chemotherapy, boosting its effectiveness in treating lung and pancreatic cancers. The drug, a CHK1 inhibitor, demonstrates significant anti-cancer activity when combined with chemotherapy in mice.
A Phase I research study is underway to develop a vaccine that could prevent recurrence of some childhood cancers in patients who have relapsed after surgery, chemotherapy and radiation. The trial has enrolled three patients so far and aims to stimulate the immune system to attack specific tumor proteins.
The trial showed that early FDG-PET-positive patients benefit from intensification of chemotherapy, leading to improved progression-free survival rates. However, omitting involved-node radiotherapy in early PET-negative patients did not demonstrate non-inferiority to the standard treatment in terms of progression-free survival.
Researchers at Cancer Research UK have identified a protein called Bcl-xL that helps cancer cells survive chemotherapy. Combining drugs targeting Bcl-xL with taxanes showed increased killing of cancer cells in the lab. This combination could improve treatment for patients receiving taxanes and reduce side effects.
Researchers found that a silver coating on catheters breaks down chemotherapy drugs, reducing treatment effectiveness. In contrast, graphene was shown not to react with the drugs, making it a promising alternative for medical equipment coatings.
Researchers developed a method to optically control microtubule inhibitor drugs with high spatial precision, allowing for targeted treatment of cancer cells. The technique uses blue light to switch on and off the drugs, eliminating systemic side effects and improving therapeutic efficacy.
Researchers found that intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events triggered by cellular senescence, providing proof-of-principal for a new treatment paradigm. The study shows that once disrupted, it takes time for the inflammatory loop to reestablish, offering hope for a safer and more effe...
Scientists discover that Methotrexate, commonly used for arthritis, can also treat myeloproliferative neoplasms with fewer side effects and lower costs. This repurposed treatment could revolutionize the care of patients worldwide.
Patients with metastatic colorectal cancer (mCRC) and quadruple wild-type genes showed significant benefit from continuing anti-EGFR therapy beyond progression. Second-line cetuximab plus FOLFOX chemotherapy improved progression-free survival, response rate, and overall survival in patients without genetic mutations.
The SENRI trial found that NK1 antagonists significantly increased the inhibition rate of vomiting and nausea, especially in females. The three-drug combination therapy of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone may be a good antiemetic treatment option for oxaliplatin-based chemotherapy in patients with colorectal c...
Researchers at Ohio State University developed nanoparticles coated with chitosan that effectively target and kill cancer stem-like cells. The study found that these nanoparticles can increase the cytotoxicity of doxorubicin without systemic toxic side effects.
Dr. Maurizio D'Incalci receives the first Pezcoller-Prodi Award in recognition of his work on translational cancer research and therapeutic oncology. The award highlights his contributions to the development of novel anticancer drugs, including trabectedin.
Researchers identified two genes, ERCC1 and TS, that can predict positive response to chemotherapy and longer survival times in metastatic colorectal cancer patients. Low levels of these genes are associated with improved survival rates when treated with oxaliplatin, while high levels may require irinotecan as the first treatment choice.
A phase III clinical trial shows necitumumab significantly improves median overall survival in stage IV squamous non-small cell lung cancer patients. The drug's 'fully human' EGFR antibody approach demonstrates potential as a novel immunotherapy strategy.
A small clinical trial found that men with advanced prostate cancer and the AR-V7 gene variant respond to chemotherapy just as well as those without the variant. The study's findings may lead to improved treatment decision-making for patients with prostate cancer.
A new study found that patients with mutated IDH genes living with anaplastic astrocytoma had a significantly longer average lifespan compared to those without the mutation. The study also suggested that radiation therapy plus temozolomide may be more effective for patients with mutated IDH.
Intravenous nutrition source Intralipid reduces chemotherapy side effects by increasing drug bioavailability and targeting cancer treatment, allowing more drugs to reach tumor sites and reducing toxicity.
Researchers found that graphene prevents damage to chemotherapy drugs and reduces potential for catheters breaking, potentially improving treatment efficacy. Graphene's biocompatibility and low toxicity make it a promising alternative coating material.
Clinical trials demonstrate improved survival rates for patients with metastatic melanoma using immune therapies nivolumab and pembrolizumab. These treatments target the 'don't attack' protein PDL1 on tumors, allowing the immune system to prime against tumor tissue.
The combination treatment induced objective responses in 67% of patients with small cell lung cancer, including 10% complete responses. Durable responses were observed, with an overall progression-free survival of 4.6 months.
The study found that nivolumab improved median overall survival by 2.4 months and doubled the one-year survival rate compared to chemotherapy. The immunotherapy drug also reduced the risk of dying from lung cancer by 41%.
A recent Mayo Clinic study found that combining the targeted drug ibrutinib with standard chemotherapy significantly reduces the risk of death or cancer progression in patients with relapsed CLL or SLL. The treatment results in a nearly 80% reduction in mortality, offering new hope for longer disease control and decreased risk of relapse.
A study has identified a possible new combination chemotherapy regimen for patients with advanced metastatic castrate-resistant prostate cancer. The treatment, combining cabazitaxel and carboplatin, significantly extended progression-free survival by 2.3 months compared to single-agent therapy.
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) provides a rational approach to grading the magnitude of clinical benefit of anti-cancer medicines. The scale will be applied to new drugs approved by the EMA, with high-scoring drugs highlighted in the ESMO Clinical Practice Guidelines.
Researchers at MD Anderson Cancer Center have identified a biomarker that may boost the response to chemotherapy in patients with ovarian cancer. The study found that miR-506 was associated with improved responses to chemotherapy drugs cisplatin and olaparib, leading to better overall survival.
A phase 1b study has shown impressive response rates of 60-75% in patients with untreated non-small cell lung cancer treated with chemotherapy and an anti-PD-L1 agent. The combination therapy was well-tolerated, with no unexpected toxicities.
New studies reveal that a vitamin pill can reduce non-melanoma skin cancer risk and docetaxel chemotherapy extends the lives of men with advanced prostate cancers. Additionally, new therapies improve outcomes for children with rare kidney cancers and adults with relapsed multiple myeloma.
Patients with locally advanced esophageal cancer who survive 5 years after surgery are at risk for recurrence, new primary cancers, and chronic pulmonary disease. Continued surveillance is necessary to mitigate these risks, particularly for patients with nodal metastases.
Breast cancer survivors experience chemo-brain, a condition characterized by chronically wandering minds and inability to focus. UBC research reveals that their brains are stuck in a disengaged state, making it difficult for them to concentrate on tasks.
Researchers from Oak Crest Institute of Science have developed a matchstick-sized subdermal implant that delivers potent antiretroviral drugs for up to 40 days, showing promise in stopping the spread of HIV. The implant eliminates adherence issues, a critical factor in HIV prevention.
Women with breast cancer who follow a physical exercise program during chemotherapy experience less fatigue, nausea, and pain. The study found that both moderate and low-intensity exercise programs significantly reduced the need for dose adjustments in chemotherapy treatment.
A study has identified molecular changes that occur in tissue after chemotherapy in ovarian cancer patients. The researchers found that these changes could be potential targets for new, more personalized drugs. The findings have the potential to advance treatments for ovarian cancer.
A common anti-fungal drug, itraconazole, has shown potential in treating metastatic prostate cancer and non-small cell lung cancer. The ReDO project is exploring its use in various cancers, offering a more affordable alternative to existing treatments.
Uninsured cancer patients pay 2-43 times more than Medicare and private insurers for chemotherapy drugs, according to a new study. The study found significant price differences for expensive and inexpensive drugs alike.
Scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma, a deadly type of brain tumor. The new method uses nanotechnology to deliver the microRNA across the blood-brain barrier, targeting multiple oncogenes at once and increasing cancer cell death.
A new study suggests that fasting combined with a class of cancer-inhibiting drugs can starve colorectal, breast and lung cancer cells, potentially replacing chemotherapy. The research found that this combination is equally effective in killing cancer cells.
Researchers have discovered a way to enhance chemotherapy's impact by inhibiting the cellular quality-control mechanism NMD, which helps breast cancer cells survive. This strategy primes cells for apoptosis and increases cell death rates.
Researchers have made progress in understanding the scientific basis for scalp cooling technology, which can help patients retain their hair during chemotherapy. The technology has also been shown to boost immune systems and aid recovery, with happier patients experiencing stronger immune responses.
A blood test identified patients with advanced colorectal cancer who could benefit from a more intensive chemotherapy regimen, reducing hair loss and other side effects. The study found that patients with higher counts of circulating tumour cells in their blood responded better to treatment.
A study by St. Jude Children's Research Hospital found that measuring residual leukemia cells in patient bone marrow during early weeks of chemotherapy helps identify high-risk patients who need intensive therapy. The technique improved survival rates for young leukemia patients, with 93.5% alive five years after diagnosis.
A phase 3 trial shows that brentuximab vedotin significantly increases progression-free survival in adults with hard-to-treat Hodgkin lymphoma. The drug was found to be well-tolerated, with side effects including peripheral neuropathy and neutropenia.
A protein called MG53 is necessary for the repair of injured kidney cells, according to a study published in Science Translational Medicine. The discovery could lead to new preventive or therapeutic treatments for acute kidney failure, which affects over 30 million Americans.
The use of the 21-gene recurrence score assay increased from 1.1% to 10.1% among Medicare beneficiaries diagnosed with breast cancer between 2005 and 2009. The majority of tests were performed in patients with intermediate-risk disease, and rates of chemotherapy remained similar during this period.
Researchers have developed nanocarriers that selectively release drugs in lung tumor areas, improving treatment efficacy by 10-25 times compared to traditional methods. This approach also reduces the total dose of medicines, minimizing undesirable effects.
Women treated with goserelin during chemotherapy experienced an 8% ovarian failure rate compared to 22% for the control group. Goserelin also improved pregnancy rates by 21% within 5 years post-treatment.
A study published in The New England Journal of Medicine found that adding goserelin to chemotherapy regimens can significantly reduce the risk of early menopause and improve fertility in young breast cancer patients. Women who took goserelin had a higher pregnancy rate and were more likely to deliver healthy babies.
Researchers at TSRI have published two studies showing how ABC transporters like P-gp change shape and react to therapeutic drugs. The findings provide clues for designing better molecules to inhibit or evade multidrug resistance.
Researchers found that patients who received chemotherapy after bladder cancer surgery had improved overall survival rates compared to those who underwent surgery alone. The study analyzed over 5,600 patients and demonstrated a significant reduction in mortality risk.
The study, which analyzed data from the National Cancer Data Base, found that 59% of women who received pre-surgery chemotherapy had breast conservation therapy. Women with larger tumors were also more likely to opt for pre-surgery chemotherapy and lumpectomy versus mastectomy.
A common antibiotic, clarithromycin, has shown potential as an anti-cancer agent when used in combination with other drugs. Low- and middle-income countries may play a key role in developing this treatment, which could lead to improved patient outcomes.
A small prospective study found no significant difference in treatment outcomes between patients with AR-V7-positive and -negative metastatic castration-resistant prostate cancer who received taxane chemotherapy. PSA responses were achieved in 41% of both groups.
A new type of self-healing hydrogel has been developed by MIT chemical engineers that can carry one or two drugs at a time. The gel consists of a mesh network made of nanoparticles and polymers that can be injected through a syringe and released over several days, targeting specific tissues and allowing for long-term drug delivery.
A study published in JAMA Oncology found that at least one clinically relevant genomic alteration was present in most samples tested, suggesting a potential for personalized therapy. The research analyzed 200 cancer of unknown primary site (CUP) samples and identified 169 specimens with potentially targetable genomic alterations.
Researchers from Brigham and Women's Hospital discovered that targeting cancer cells immediately after chemotherapy can make them more vulnerable to treatment. The 'one-two punch' approach involves administering two drugs simultaneously or sequentially, increasing the effectiveness of cancer therapy.
G1 Therapeutics, a UNC-Chapel Hill spinout, has secured $33 million in Series B funding to accelerate clinical development of its lead CDK4/6 inhibitor for cancer treatment. The company aims to develop more effective and less toxic methods to treat patients with cancer.
Research suggests that immuosuppressives and anti-cancer drugs can reanimate hepatitis B in previously infected individuals, according to a study published in Hepatology. The study authors emphasize the importance of routine screening for HBV before starting treatment with immunosuppressives or anti-cancer drugs.
Two major studies strengthen the case for abiraterone as a treatment option for men with advanced prostate cancer. The trials found that receiving abiraterone before chemotherapy significantly extended men's lives by an average of four months, compared to those who did not receive it.